James Kelly Ganjei serves as Executive at Inmune Bio, Inc., where they oversee executive responsibilities. Since joining the company, James Kelly Ganjei has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Mar 22, 2022 involved receiving (via award) 17,793 shares valued at $150.0K.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Mar 22, 2022 | INMB | $150.0K | Award | 17,793 | $8.43 | Discretionary |
James Kelly Ganjei currently holds 17,793 shares of Inmune Bio, Inc. (INMB), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, James Kelly Ganjei has been a net neutral trader of INMB stock. They have purchased $0 and sold $0 worth of shares.
James Kelly Ganjei's most recent insider trade was on Mar 22, 2022, when they sold 17,793 shares at $8.43 per share.
Get notified when new Form 4 filings are submitted